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In the context of type 2 diabetes, inter-individual variability in the therapeutic response of
blood glucose control to exercise exists to the extent that some individuals, occasionally
referred to as “non-responders,” may not experience therapeutic benefit to their blood
glucose control. This narrative review examines the evidence and, more importantly,
identifies the sources of such inter-individual variability. In doing so, this review highlights
that no randomized controlled trial of exercise has yet prospectively measured inter-
individual variability in blood glucose control in individuals with prediabetes or type 2
diabetes. Of the identified sources of inter-individual variability, neither has a prospective
randomized controlled trial yet quantified the impact of exercise dose, exercise
frequency, exercise type, behavioral/environmental barriers, exercise-meal timing, or
anti-hyperglycemic drugs on changes in blood glucose control, in individuals with
prediabetes or type 2 diabetes. In addition, there is also an urgent need for prospective
trials to identify molecular or physiological predictors of inter-individual variability in the
changes in blood glucose control following exercise. Therefore, the narrative identifies
critical science gaps that must be filled if exercise scientists are to succeed in optimizing
health care policy recommendations for type 2 diabetes, so that the therapeutic benefit
of exercise may be maximized for all individuals with, or at risk of, diabetes.
Keywords: exercise, training, type 2 diabetes, non-responder, variability, blood glucose control, HbA1c,
heterogeneity
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is characterized by persistent hyperglycemia (Table 1) that
increases the risk of retinopathy, nephropathy, neuropathy, and cardiovascular-related mortality.
Because diabetes affects 5–10% of the population, healthcare costs create a major socioeconomic
burden. For example, in 2012 the United Kingdom, the National Health Service spent ∼10% of
its annual budget (∼£24billion) on diabetes management (Hex et al., 2012). Although T2DM is
considered a preventable disease, since its incidence is mostly associated with lifestyle factors,
patient numbers continue to escalate.
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Blood glucose levels are governed by rates of glucose
appearance and disappearance that are controlled by a complex
interplay between metabolic, endocrine, and neurological
systems. This involves direct action of neuronal, gastrointestinal,
hepatic, pancreatic, renal, adipose, endothelial, and muscular
tissues. Muscle contraction-mediated increases in basal glucose
disposal were first documented in the 1960s (Holloszy and
Narahara, 1965). In the 1970s and 1980s, it emerged that exercise
also increases insulin sensitivity in rodents (Richter et al., 1982)
and humans (Soman et al., 1979). An abundance of studies has
now confirmed that robust increases in insulin sensitivity occur
following exercise in individuals with prediabetes or patients with
T2DM. Consequently, exercise is a key part of diabetes therapy
included in the American Diabetes Association’s (ADA) diabetes
prevention and treatment guidelines. Skeletal muscle indeed
plays a large role in blood glucose uptake during/following
exercise, but at rest and following a meal blood glucose levels are
controlled by several tissues. Skeletal muscle insulin sensitivity
is not measured in the clinic since it is impractical and because
it is the exposure to persistent hyperglycemia (in additional to
elevated lipids and inflammatory cytokines) that elicits diabetic
complications and cardiovascular mortality. For this important
reason, this review will principally focus on evidence from
exercise intervention studies where blood glucose control is the
primary outcome. Glycated hemoglobin (HbA1c) levels, fasting
plasma glucose, and the 2-h plasma glucose value during a 75-g
oral glucose tolerance test (OGTT) are the three variables used
by clinicians to measure blood glucose control, and to diagnose
and monitor treatment in those at risk of developing diabetes
and in patients with T2DM (American Diabetes Association,
2018a) (Table 1).
Although there is a robust effect of exercise on insulin
sensitivity, the effect of exercise training on blood glucose
control is less consistent. Several reports suggest that large
inter-individual variability may exist in the therapeutic effect
of exercise on blood glucose control. This narrative review will
explore such variability and then identify the sources of this
variability. By doing so, the narrative will highlight key science
gaps that must be filled in order to inform and improve the
current clinical guidelines.
EVIDENCE FOR INTER-INDIVIDUAL
VARIABILITY IN THE THERAPEUTIC
EFFECT OF EXERCISE ON BLOOD
GLUCOSE CONTROL, IN INDIVIDUALS
WITH (PRE)DIABETES
Clues that inter-individual variability exists have emerged from
clinicians’ anecdotal observations and alarmist media headlines.
However, we can venture beyond subjective assessments and
objectively examine such variability. The first evidence comes
from the HERITAGE family study in which Boulé and colleagues
followed 596 healthy sedentary individuals through a 20-
week training intervention (Boulé et al., 2005). Participants
exercised on cycle ergometers for 30–50-min on 3 days/week,
TABLE 1 | Diagnostic references range values for high risk for diabetes
(prediabetes) and type 2 diabetes (American Diabetes Association, 2018a).
Prediabetes Type 2 diabetes
Fasting glucose ≥5.6 to 6.9 mM ≥7 mM
Two-hour OGTT glucose ≥7.8 to 11 mM ≥11.1 mM
HbA1c ≥5.7 to 6.4%
(39–47 mmol/mol)
≥6.5% (48 mmol/mol)
Random blood glucose – ≥11.1 mM
at 55–75% VO2max. Glucose tolerance and its determinants
(insulin sensitivity and insulin secretion) was determined via
intravenous glucose tolerance tests (IVGTT) before and after
the intervention. Although there were statistically significant
training-induced increases in glucose disappearance rate (Kg),
insulin sensitivity (Si), and disposition index (DI, a marker
of insulin secretory function relative to insulin sensitivity),
approximately 40% of the participants showed no change or
an adverse direction of change (a decrease) in these variables
(Boulé et al., 2005). Fasting glucose also significantly improved
but its inter-individual variability was not reported. This work
made an important advance by presenting the variability of
training-induced changes in diabetes-relevant variables; however,
participants with prediabetes or T2DM were not included, and
neither HbA1c nor 2-h OGTT glucose were measured (Boulé
et al., 2005). We followed up this work in 2013 to examine the
inter-individual variability in the therapeutic response of blood
glucose control in 105 older obese individuals with prediabetes
or T2DM, excluding those treated with insulin (Solomon et al.,
2013b). All participants underwent a 12–16-week aerobic exercise
training intervention consisting of up to 60 min/day supervised
walking or cycling on 4–5 days/week at up to 75% of VO2max.
Blood glucose control (HbA1c, fasting glucose, 2-h OGTT
glucose) and its determinants, insulin sensitivity (measured
by hyperinsulinemic euglycemic clamp) and insulin secretion
(plasma C-peptide response to OGTT), were assessed before and
following the intervention. Exercise training was well adhered to
and there was a small statistically significant reduction in both
fasting glucose and 2-h OGTT glucose, along with an statistically
significant increase in insulin-sensitivity and disposition index
(Solomon et al., 2013b). Following training, HbA1c, fasting
glucose, and 2-h OGTT glucose were reduced in only 69, 62,
and 68% of the study participants, respectively (Solomon et al.,
2013b). This work indicated that approximately 1/3 of this cohort
of individuals with prediabetes or T2DM had no improvement or
even a deterioration in blood glucose control following exercise
training (Figure 1). We confirmed that the observations made
by Boulé et al. (2005) in healthy individuals are also evident
in individuals with pathological blood glucose control. Similar
findings were published in Álvarez et al. (2017) who examined
the effect of 10-weeks of high-intensity interval training in two
groups of women, 20 with normal fasting glucose and 20 with
impaired fasting glucose and elevated HOMA-IR values. The
authors found a statistically significantly reduction in HOMA-
IR but an increase in HOMA-IR in 5 of the 20 participants
(Álvarez et al., 2017). In the same year, work from Phillips and
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FIGURE 1 | A cartoon depicting the inter-individual variability of changes in HbA1c levels following exercise training in individuals with prediabetes or type 2 diabetes.
The y-axis represents the training-induced change in HbA1c (post- minus pre-intervention value). The x-axis represents the individual participants taking part in a
study. Adverse outcomes are illustrated as participants’ responses showing a training-induced increase in HbA1c that is more than 1.96 times the technical error
(TE). Therapeutic outcomes are shown as training-induced decreases in HbA1c that are greater than 1.96 times the technical error.
colleagues also highlighted variability in changes in HOMA-IR
following training in obese or prediabetic individuals (Phillips
et al., 2017). It must be highlighted, however, that neither our
work (Solomon et al., 2013b) or the work of Boulé (Boulé
et al., 2005), or Álvarez (Álvarez et al., 2017), included a non-
exercise control group. Therefore, the direct effects of training
per se are uncertain, and the natural variability (i.e., intra-subject
variability) in the measured variables over the time course of the
interventions are not known. The work from Phillips did include
a non-exercise control group but did not report variability from
diabetes-related clinical diagnostics (HbA1c, or blood glucose)
(Phillips et al., 2017). More importantly, as will be discussed in the
next section, despite concluding that inter-individual variability
in the therapeutic effect of exercise on blood glucose control
exists, it can be debated whether these studies employed an
adequate study design in order to detect such variability and thus
accurately identify adverse outcomes.
HOW SHOULD WE QUANTIFY
INTER-INDIVIDUAL VARIABILITY AND
THEREBY IDENTIFY A
NON-RESPONDER TO EXERCISE?
As the previous section alludes, inter-individual training-induced
changes in blood glucose control are heterogeneous across the
population. The treatment goal for diabetes is to manage blood
glucose control by reducing HbA1c, fasting glucose, and 2-h
OGTT glucose toward specific target levels. A “non-responder”
is a patient displaying a lack of therapeutic benefit (no reduction
in HbA1c, in the context of this review) following treatment,
while a deterioration in blood glucose control (i.e., an increase
in HbA1c) is an “adverse outcome” since this confers an
elevated risk of diabetic complications and cardiovascular-related
mortality. Previously, this phenomenon has also been referred
to as “exercise resistance” (De Filippis et al., 2008; Stephens and
Sparks, 2015). Several randomized controlled trials have found no
significant improvement in blood glucose control in patients with
T2DM following training (Dela et al., 2004; Burns et al., 2007;
Karstoft et al., 2013; Terada et al., 2013b). However, these studies
present the changes in sample mean (±SD, or±SEM) and do not
provide information regarding the inter-individual responses.
To obtain an accurate assessment of the inter-individual
variability in an intervention-induced change in a primary
outcome variable, one must be able to quantify the two
components of change: random change (induced by technical
and/or biological error) and systematic change (induced by the
intervention). To separate random from systematic changes,
scientists may calculate the typical error of measurement
(i.e., the within-subject standard deviation), which reflects the
measurement-to-measurement variation in a patient’s value.
Typical error is equal to the standard deviation of the sum
of the observed differences between repeated measurements
within each individual. Since variance is equal to standard
deviation squared (s2), the variance of the differences between
within-subject repeated-measurements (represented by sdiff 2) is
equal to the sum of the variances representing the typical error.
This can be written as sdiff 2 = s2 + s2 which rearranges to
s = sdiff /√2, therefore the technical error of measurement is
equal to the standard deviation of the difference scores divided
by the square root of 2. For normally distributed data, 95% of
the observations fall within 1.96 standard deviations of the mean.
Therefore, to have 95% confidence that an intervention (either
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treatment or control) has no effect on a variable of interest in a
particular individual and thereby identify a non-responder, the
intervention-induced change in that subject should be less than
1.96 times the technical error of measurement. In the context
of this review, any diabetic patient not exhibiting an exercise-
induced decrease in HbA1c (or fasting glucose or 2-h OGTT
glucose) more than 1.96 times the technical error would be a true
non-responder. These principles have been discussed in detail
by Hopkins (2000) and Senn (2004). Technical error, however,
may display heteroscedasticity. For example, it could be greater
when the value of the variable is larger, or it may differ across
sub-groups (e.g., male vs. female, young vs. old, diabetic vs. non-
diabetic, etc.). If so, applying an average typical error to all groups
may overestimate some individuals and underestimate others. To
account for heteroscedasticity, the typical error of measurement
would need to be calculated individually for all such sub-groups
or, more simply, the data could be normalized; for example,
by log transforming to remove the heteroscedasticity or by
expressing the technical error as a percentage of the respective
mean (i.e., a coefficient of variation for the technical error). But,
how should we use technical error to quantify inter-individual
variability?
In a repeated-measures study, if data are analyzed using
a linear mixed model with the patient ID number as a
random effect and the intervention assigned as a fixed effect, a
significant patient-by-treatment interaction would indicate true
inter-individual variability. However, this would only be correct
if the training effect on an individual is reproducible. Naturally,
the blood glucose lowering response to exercise training in T2DM
may not only exhibit inter-individual variability but also intra-
individual variability of the measurement if the intervention
was repeated within an individual. Consequently, the optimal
approach for quantifying inter-individual variability in repeated-
measures studies is to use a randomized replicated crossover
design where the control (no training) and treatment (training)
conditions are administered to each participant at least twice
(Senn et al., 2011; Hecksteden et al., 2015; Atkinson et al., 2018;
Goltz et al., 2018) (Figure 2). This design would allow accurate
interpretation of a significant patient-by-treatment interaction,
thereby revealing the true individual differences in response
to exercise. A limitation of this approach, however, is that an
adequate wash-out of the training effects would be required
which, for exercise studies, creates logistical difficulty. It is
unlikely that long-term training studies with a double crossover
to determine the patient-by-treatment interaction effect on blood
glucose control will ever be conducted in patients with T2DM
(Figure 2), because blood glucose control would deteriorate
while patients were not exercising, and several confounding
variables would likely change (e.g., their drug regimen, body
weight, etc.). Hecksteden et al. (2015) proposed an indirect
approach whereby a separate validity study would be conducted
to determine the within-subject variability in their response
to repeated training interventions and using a linear mixed
model to apply that to the main study. Although not in
the context of blood glucose control or in individuals with
(pre)diabetes, some training studies have used this approach
(Bonafiglia et al., 2016; Gurd et al., 2016) but it is confounded
FIGURE 2 | (A) A schematic for a repeated-measures double-crossover study
design which, if the patient-by-treatment interaction term were statistically
significant, would accurately indicate the presence of inter-individual variability.
All patients undergo all interventions twice. The type of trial each participant
first undergoes should be randomized and the primary outcome is measured
at the beginning and the end of each intervention period. The time between
interventions would have to be sufficient such that training effect was washed
out. (B) Perhaps a more practical and logistically feasible method for
determining the technical error of measurement, and thereby identifying
non-responders, is a randomized controlled intervention where the primary
outcome variable is measured repeatedly within an intervention. Participants
are randomized to either the control arm (no training) or the treatment arm
(exercise training). Ideally, the variable would be repeatedly measured within a
time frame where intervention-induced changes are unlikely (e.g., measuring
HbA1c three times within a 2-week period towards the end of a long-term
training intervention). Gray stars indicate repeated measurement of the
variable, HbA1c, for example.
by assumed generalizability, which contradicts the initial reason
to accurately determine whether true inter-individual variability
actually exists. Fortunately, a more practical alternative solution
exists which is to repeatedly test the primary outcome variable
within an intervention. Bouchard et al. (2012) explored inter-
individual variability in the response of metabolic syndrome
related variables to exercise training in order to identify adverse
outcomes. They used an approach whereby resting systolic
blood pressure, fasting triglycerides, and fasting HDL-cholesterol
were measured three times over a 3-week period in sixty
subjects from six independent randomized controlled long-
term exercise training studies (including HERITAGE, DREW,
INFLAME, STRRIDE, and others). Subsequently, they calculated
the technical error of measurement for these variables to
determine the frequency of exercise-induced adverse outcomes,
reporting that 12, 10, and 13% of their sample population had
an “adverse response” in systolic blood pressure, triglycerides,
and HDL-cholesterol, respectively, following exercise training
(Bouchard et al., 2012). While this elegant approach, which
was also used by Phillips et al. (2017), provides evidence
that non-responders to exercise indeed exist in the context
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of cardiometabolic risk factors, surprisingly the authors of
neither study presented inter-individual changes in blood
glucose control. Blood glucose control (2-h OGTT glucose) was
measured, however, by De Lannoy et al. (2017) who found
that the number of non-responders ranged from 86 to 98%
following different types of training in 171 obese non-diabetic
adults.
The above-mentioned studies provide evidence for inter-
individual variability in the therapeutic effect of exercise
on blood glucose control, in individuals with (pre)diabetes.
However, as of 2018, there is an urgent need for a large-scale
randomized controlled trial aimed specifically at investigating
the variability of long-term training adaptations in blood
glucose control in individuals with T2DM. Such a trial should
employ a study design allowing analysis of a patient-by-
treatment interaction. This would be possible with a repeated-
measures crossover where the control and treatment conditions
are administered to each participant at least twice, or where
the primary outcome variable (HbA1c, fasting glucose, and
2-h OGTT glucose) is repeatedly tested within the control
and treatment intervention arms (Figure 2). As described
above, both approaches have their limitations that investigators
need to be aware of. But such approaches would generate
technical errors of measurement, enabling training-induced
effects on blood glucose control to be reliably compared
between independent studies, and allowing interpretations to
be made in the context of clinically meaningful responses to
interventions in individual subjects. The eternal endeavor of
achieving statistical significance between means is useless when
trying to identify whether one particular person has responded
or not to a treatment. Therefore, measuring technical error,
quantifying inter-individual variability, and thereby detecting
true adverse outcomes in exercise science will advance the
field. However, this will only be achieved if investigators
also attempt to control for as many sources of variance as
possible.
SOURCES OF INTER-INDIVIDUAL
VARIABILITY IN THE THERAPEUTIC
EFFECT OF EXERCISE ON BLOOD
GLUCOSE CONTROL IN INDIVIDUALS
WITH (PRE)DIABETES
The above-described evidence suggests it is very likely that inter-
individual variability in the therapeutic effects of exercise on
blood glucose control truly exists in patients with T2DM, and
that adverse outcomes do occur. However, we do not precisely
understand what causes adverse outcomes and, more importantly
therefore, we do not currently know how adverse outcomes can
be prevented. The standard-of-care guidelines for diabetes which
are published annually by the American Diabetes Association,
provide excellent, clear and effective evidence-based exercise
recommendations that are summarized in Table 2 (American
Diabetes Association, 2018b). However, heterogeneity in the
therapeutic effect of exercise between patients inevitably prompts
us to explore how adverse outcomes can be avoided. Exercise
scientists, clinicians, and fitness trainers often comment that non-
responders should simply do more exercise. It is indeed enticing
to believe such a sentiment, particularly when it may be true
in the context of improving cardiorespiratory fitness (VO2max)
in healthy adults (Montero and Lundby, 2017). Nonetheless, in
individuals with (pre)diabetes, several lines of published evidence
have identified sources of inter-individual variability in the
therapeutic effect of exercise on blood glucose that go beyond
exercise dose. The following points discuss these sources in the
context of current guidelines which, with future experimental
evidence, will be improved by providing more information on
exercise dose, exercise type, exercise-meal timing, and anti-
hyperglycemic drug-exercise timing, etc.
A. Exercise Dose (Frequency, Intensity,
and Time)
The first evidence that exercise dose might contribute to the
inter-individual variability of training-induced changes in blood
glucose control came from the elegant series of STRRIDE
studies. In 2004, over 200 middle-older aged, sedentary,
overweight or obese individuals were randomized to one of
four 8-month training interventions: (i) low amount/moderate
intensity (1200 kcal/week), (ii) low amount/vigorous intensity
(1200 kcal/week), (iii) high amount/vigorous intensity
(2000 kcal/week), or (iv) non-exercise control. Fasting glucose,
and insulin sensitivity, insulin secretion, and disposition index
(modeled from an IVGTT), were measured before and after
the interventions. Fasting glucose increased in the control
group but was unaffected by any of the training interventions,
whereas insulin sensitivity was most increased by the low
amount/moderate intensity and high amount/vigorous intensity
interventions compared to the low amount/vigorous intensity
intervention (Houmard et al., 2004; Slentz et al., 2009). Of
importance, the expected training-induced compensatory
decrease in the insulin secretory response to IVGTT (relative
to the increased insulin sensitivity) was smallest following the
TABLE 2 | Exercise recommendations for adults with prediabetes or type 2 diabetes, issued in American Diabetes Association (2018b) standard of care update.
Exercise recommendations for adults with prediabetes or type 2 diabetes
1 ≥150 min of moderate to vigorous intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity.
2 Shorter duration (≥75 min per week) of vigorous-intensity or interval training may be sufficient for younger and more physically fit individuals.
3 Two to three sessions per week of resistance exercise on non-consecutive days.
4 Decrease the amount of time spent in daily sedentary behavior. Prolonged sitting should be interrupted every 30 min.
5 Flexibility training and balance training are recommended 2–3 times per week for older adults with diabetes.
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low amount/moderate intensity intervention, leading to the
largest increase in glucose disposition in that group (Slentz
et al., 2009). The STRRIDE investigators also followed up
these investigations in ∼150 middle- to older-aged, sedentary
participants with prediabetes randomized to one of four
6-month interventions: (i) low amount/moderate intensity
exercise, (ii) high amount/moderate-intensity exercise, (iii) high
amount/vigorous-intensity exercise, or (iv) control group (low
amount/moderate intensity plus 7% weight loss to mimic the
DPP study). This STRRIDE-Prediabetes study (Slentz et al.,
2016) found that only the control group improved fasting
glucose but that high amount/moderate-intensity exercise was
most effective for lowering the blood glucose during OGTT,
when compared to either low amount/moderate intensity or
high amount/vigorous-intensity exercise. A further study (Malin
et al., 2013) found that exercise dose was positively associated
with increased glucose disposition index following a 3-month
aerobic training intervention in 35 older, obese, individuals with
prediabetes. However, no statistically significant associations
between exercise dose and changes in blood glucose control
were found (Malin et al., 2013). Furthermore, exercise dose
was simply estimated from assumed energy expenditure during
exercise sessions in a supervised training intervention and
participants were not randomized to different exercise dosing
groups (Malin et al., 2013). Finally, Terada and colleagues
conducted a retrospective analysis of outcomes in 15 middle-
to older-aged individuals with T2DM randomly assigned to a
12-week energy expenditure-matched high-intensity interval
exercise or moderate-intensity steady-state exercise intervention
(Terada et al., 2013a). Capillary blood glucose was measured
immediately before and after each exercise bout and multiple
regression analyses demonstrated that greater reductions in
blood glucose were found in individuals working at higher
exercise intensities or engaged in longer exercise bouts (45- or
60- vs. 30-min). Hence, Terada et al. (2013a) showed that a larger
exercise dose was more effective for reducing hyperglycemia in
diabetes patients.
Exercise frequency has seldom been studied during training
interventions in the context of diabetes. Dubé et al. (2012), who
studied the effects of 16-weeks of aerobic exercise training on
changes in insulin sensitivity in middle-aged overweight and
obese non-diabetic individuals, found that although exercise
dose was positively correlated with increased insulin sensitivity,
exercise frequency did not contribute to the magnitude of the
change. Unfortunately, Dubé and colleagues did not report blood
glucose control variables (Dubé et al., 2012). Exercise frequency
has, however, been studied in detail in people with (pre)diabetes
during a 24–48-h period. In van Dijk et al. (2012) found that
a 30-min cycle at 50% peak power on two consecutive days
elicited the same improvement in continuous glucose monitoring
(CGM)-derived blood glucose control compared to a single
60-min ride in thirty older obese patients with T2DM. DiPietro
et al. (2013) found that three 15-min post-meal walking bouts
(moderate-intensity; 3 METs) was more effective at lowering
CGM-derived blood glucose profiles than a single 45-min bout
performed in the morning or evening, in older adults with
prediabetes. In a similar demographic of prediabetic adults, in
Francois et al. (2014) also found that walking bouts (6 × 1 min
incline walking at 90% HRmax) performed 30 min before the
three meals of the day reduced CGM-derived glucose compared
to no exercise or a single 30-min bout of moderate-intensity
(60% of maximal heart rate) walking. However, these studies
(DiPietro et al., 2013; Francois et al., 2014), along with the work of
Dubé et al. (2012) did not present the inter-individual responses.
While some studies indicate that exercise dose may indeed
influence variability in the changes in blood glucose control
following training in people with (pre)diabetes, no study has
yet specifically analyzed the inter-individual variability caused by
different exercise doses or frequency. While current guidelines
(Table 2) for preventing and treating T2DM clearly state how
many minutes of exercise should be accumulated each week and
how frequent exercise sessions should be (American Diabetes
Association, 2018b), precise guidance on what a moderate to
vigorous intensity equates to is lacking.
B. Exercise Type
Evidence that the type of exercise might play a role in the
inter-individual variability in outcomes also originates from the
STRIDE team. In 2011, the STRRIDE-AT/RT study randomized
∼200 volunteers to (i) resistance training (3 days/week, 3 sets/day
of 8–12 repetitions of 8 different exercises targeting all major
muscle groups), (ii) aerobic training (∼120 min/week at 75%
of the VO2max), or (iii) combined resistance plus aerobic
training, for 8-months (Bateman et al., 2011). Although the
post-minus pre-intervention change in blood glucose increased
in the combined resistance-aerobic group and decreased in
the aerobic-only and resistance-only group, the large standard
error of the change scores indicates probable heterogeneity
between subjects. Consequently, the authors found no statistically
significant effects of exercise on fasting blood glucose nor
statistical differences between groups (Bateman et al., 2011). The
HART-D and DARE studies advanced this work by conducting
randomized controlled trials comparing the effects of resistance,
aerobic, vs. combined resistance-aerobic training on HbA1c in
patients with T2DM (Sigal et al., 2007; Church et al., 2010).
Both studies employed similar designs, training sessions were
fully supervised, but HART-D was longer in duration than
DARE (9- vs. 6-months) and made more thorough recording
and monitoring of the exercise dose and energy expenditure.
HART-D found that only combined resistance-aerobic training
significantly reduced HbA1c (Church et al., 2010), while HbA1c
was significantly reduced in all 3 exercise groups the DARE
trial (Sigal et al., 2007). The between-study differences may
be attributable to the greater weight loss (fat mass) seen in
DARE vs. HART-D. Further to such work, a randomized
controlled trial from my group compared the effects of 4-
months of moderate-intensity steady-state walking training (4–
5 days/week, ∼60 min/day) vs. energy expenditure matched
moderate-intensity interval walking training (ten cycles of 3-
min fast, 3- min slow walking) in patients with T2DM (Karstoft
et al., 2013). We found that only interval walking training
improved CGM-derived glucose control but that this was in
the presence of greater weight loss than the continuous walking
group. We also found that varying interval length (1-min fast,
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1 min slow vs. 3-min fast, 3- min slow walking) had no influence
on the improvement in blood glucose control (Jakobsen et al.,
2016).
The current guidelines (Table 2) do not provide specific
guidance on which types of exercise may be used (American
Diabetes Association, 2018b). Neither are they explicit on what
aerobic or resistance exercise means. Some studies indeed
indicate that either aerobic or resistance exercise alone may
be sufficient to improve blood glucose control, while other
work shows that different modalities of walking can also have
diverging outcomes. In an age of interval training popularity,
since 2017 the ADA guidelines have included a useful statement
concerning vigorous exercise and interval training (American
Diabetes Association, 2018b), stating that “≥75 min/week of
vigorous-intensity or interval training may be sufficient for
younger and more physically fit individuals.” However, specific
details on what vigorous-intensity or interval exercise may entail
is lacking. We also await outcomes from large scale randomized
controlled trials with HbA1c as a primary endpoint to further
understand the role of exercise type (particularly high intensity
interval training) in order to further optimize existing guidelines.
Additionally, no current study has yet prospectively examined
inter-individual variability in changes in blood glucose control
following different types of training in patients with prediabetes
or T2DM.
C. Exercise Adherence
In this context, adherence refers to the longevity of maintaining
regular exercise following the initial inclusion of exercise to
an individual’s lifestyle. With the exception of a few studies
(Houmard et al., 2004; Sigal et al., 2007; Slentz et al., 2009;
Church et al., 2010; Karstoft et al., 2013; Solomon et al.,
2013b), exercise adherence is seldom measured or reported
in training studies whose primary outcome was blood glucose
lowering in (pre)diabetes patients. This is unfortunate since
adherence is of utmost importance for assessing the intended
stimulus provided by the intervention. That said, many trials
exclude patients participating in <80% of the treatment
intervention. This creates widespread homogeneity and bias.
Nonetheless, a lack of adherence will clearly influence the total
exercise dose (daily dose, weekly frequency), which as described
above contributes toward inter-individual outcomes. However,
exercise adherence goes beyond metabolism and involves health
psychology (desire, motivation), behavioral barriers (e.g., self-
esteem, self-image), and environmental barriers (e.g., local
access to trails/parks/gyms, weather, climate). Such factors are
beyond the scope of this review but have been reviewed
elsewhere (Wing et al., 2001). Nonetheless, in the interest of
implementing and sustaining population-wide physical activity
lifestyles changes, a brief description of the influence of such
factors on exercise adherence should be included in the
current ADA guidelines. This may help clinicians provide more
individualized advice. Furthermore, the role of adherence in
the inter-individual variability in glycemic outcomes following
training in (pre)diabetes patients must be studied in greater
depth. This would help inform and further enhance the
guidelines.
D. Exercise-Meal Timing
Training in the fed vs. fasted state has long been an intense
area of investigation for optimizing athletes’ training methods
to maximize their performance. This is also true for patients
with type 1 diabetes, where several studies have investigated
exercise timing in relation to insulin dosing and carbohydrate
intake. However, in the context of T2DM, little data exists. In the
early 2000s, a series of elegant studies by Poirier and colleagues
(Poirier et al., 2000, 2001; Gaudet-Savard et al., 2007) examined
fed vs. fasted exercise in men with T2DM. One-hour of moderate-
intensity cycling (60% VO2max) completed 2-h after breakfast
reduced blood glucose, whereas fasted exercise did not (Poirier
et al., 2001). Further, following a 3-month training intervention
(1-h of cycling at 60% VO2max, three times per week) no change
in blood glucose was found when exercise was performed in
the fasted state, whereas 20–40% decreases in blood glucose
arose when exercise was initiated postprandially (Poirier et al.,
2000). However, the authors also documented that the effect
of exercise on blood glucose in the fasted state was dependent
on the ambient glucose level: blood glucose increased when
pre-exercise glucose levels were ≤6 mM but decreased when
pre-exercise levels were >8 mM (Gaudet-Savard et al., 2007).
In support of these findings, Colberg et al. (2009) found that
20 min of self-paced treadmill walking 15–20 min after eating
dinner lowered blood glucose in patients with T2DM, whereas
pre-dinner exercise had no effect on blood glucose levels. Data
somewhat related to these observations were generated from
a retrospective analysis of outcomes from a 12-week training
study in patients with T2DM conducted by Terada et al. (2013a).
They demonstrated that greater reductions in blood glucose were
found when pre-exercise meals were ingested less than 2-h prior
to the beginning of exercise sessions rather than more than 2-h.
These above-described data led to a series of view-point papers
published by Chacko (2014, 2016) who presented an idea that the
mid-postprandial period (30–120 min post-ingestion) would be
the best time to implement exercise in order to optimize blood
glucose control. While Chacko’s viewpoints are mostly anecdotal
and informed by educated opinion rather than evidence, they
nicely highlighted the necessity for research data in this field
from a clinician’s perspective. That said, Chacko’s points are
specific to the acute response to exercise. In healthy individuals,
ingestion of carbohydrate prior to exercise has been shown to
blunt adaptations to training (Van Proeyen et al., 2010) as well as
acute bouts of exercise (Gonzalez et al., 2013; Taylor et al., 2018).
Thus optimal benefit may be conferred from fasted exercise.
However, in people with diabetes, fasted exercise promotes post-
exercise hypoglycemia which should be avoided at all costs.
Exercise-meal timing is rarely considered in the design
of training studies. As of 2018, no long-term, randomized,
controlled, physical activity or exercise intervention trial with a
primary focus on blood glucose control has reported exercise-
meal timing. It is therefore possible that inappropriate exercise-
meal timing partly explains the lack of improvement in
blood glucose control in some long-term training studies in
individuals with (pre)diabetes (Dela et al., 2004; Burns et al.,
2007; Karstoft et al., 2013; Terada et al., 2013b). Despite
efforts to elucidate the optimal exercise-meal timing, full
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knowledge in this area is lacking. Consequently, as of 2018,
no information regarding exercise-meal timing is provided
in the ADA guidelines for preventing and treating T2DM
(American Diabetes Association, 2018b). Furthermore, no study
has yet determined the influence of exercise-meal timing on
inter-individual variability in glycemic outcomes. Given recent
knowledge that skeletal muscle metabolism in humans follows
a diurnal pattern under the control of clock genes (Loizides-
Mangold et al., 2017), it is plausible that circadian rhythm is
an additional (albeit complicated) factor to additionally consider
in future work aimed at optimizing exercise-meal timing for
maximal postprandial glucose control.
E. Exercise-Drug Interactions
Anti-hyperglycemic pharmacologic therapy is administered in
conjunction with lifestyle management for the treatment of,
and to an extent the prevention of, T2DM. At first, metformin
monotherapy is initiated to lower hepatic glucose output. If this
is not successful at achieving HbA1c targets, dual or triple therapy
with various insulin sensitizers (e.g., TZDs like pioglitazone),
insulin secretagogues (e.g., sulfonylureas like glimepiride, or
GLP-1 receptor agonists like liraglutide), DPPIV inhibitors
(e.g., sitagliptin), or sodium-glucose cotransport inhibitors (e.g.,
canagliflozin) is initiated, with additional insulin injection
therapy if HbA1c targets are still not achieved (American
Diabetes Association, 2018c). Because pharmacologic therapy is
always administered in conjunction with lifestyle management
(diet and exercise), it is highly likely that a patient with
T2DM who initiates exercise will also be using some anti-
hyperglycemic medication. Since exercise affects most of the
molecular pathways these compounds target, it is a clinical
necessity that researchers understand exercise-drug interactions.
Fortunately, several studies have examined this topic.
Sharoff et al. (2010) found that metformin (2000 mg
twice/day for 2–3 weeks) did not augment the insulin sensitizing
effect of exercise (40-min cycling at 65% VO2peak) in non-
diabetic individuals and may even blunt the beneficial effects
of exercise. They followed up by examining the effects of 12-
weeks of exercise training (45-min of cycling at 75% HRmax
3-times/week and 2-sets of 12-rep max lifts for all major muscle
groups 2-times/week) ± metformin treatment (2000 mg/day)
in prediabetic individuals (Malin et al., 2012). They found that
the largest increase in insulin sensitivity was present in the
exercise only group, compared to the exercise plus metformin and
metformin-only groups (Malin et al., 2012). Neither study found
an effect on fasting glucose, while HbA1c and OGTT data were
not reported. The notion that an interaction between exercise
and metformin may blunt therapeutic benefits was supported
by a small study in patients with T2DM from Boulé et al. (2011)
which showed that exercise reduced the metformin-induced
lowering of blood glucose responses to a meal. However, a
larger-scale but retrospective analyses of the DARE trial in
patients with T2DM from the same authors (Boulé et al., 2013)
showed that improvements in HbA1c following 22-weeks of
either aerobic, resistance, or combined aerobic plus resistance
training, were not different between metformin users (N = 143)
and non-users (N = 82). Erickson et al. (2017a) examined
T2DM patients treated with either metformin monotherapy
or metformin combined with additional antidiabetic drugs
(sulfonylureas, GLP-1 receptor agonists, or DPPiv inhibitors)
(Erickson et al., 2017b). They found that post-meal treadmill
walking (five 10-min bouts at 60% VO2max, or three 10-min
bouts at 50% VO2max) reduced postprandial glucose responses
in habitual metformin users but that benefits were blunted in
those on additional therapy (Erickson et al., 2017a,b). Such
studies support the use exercise for managing blood glucose in
drug-treated diabetes patients, but had a very small sample size
(N = 8–10) and were not specifically designed to test exercise-
drug interactions.
Besides metformin, several groups have examined exercise-
drug interactions for other anti-diabetic drugs. In a longitudinal
study by Mensberg et al. (2014), 33 T2DM patients were
randomly allocated to 16-weeks of exercise (combined aerobic
and resistance) and the GLP-1 receptor agonist, liraglutide
(1.8 mg/day), or exercise and placebo (Mensberg et al., 2014). The
authors found that HbA1c and fasting glucose were more greatly
reduced in the liraglutide-treated group, indicating a beneficial
interaction between exercise and GLP-1 receptor agonist therapy
for blood glucose management (Mensberg et al., 2014). However,
the liraglutide-treated patients also lost more weight, negating
the specificity of an exercise-liraglutide interaction directly
optimizing glucose control (Mensberg et al., 2014). With a
focus on skeletal muscle, using fluorine-18–labeled fluoro-deoxy-
glucose and positron emission tomography (PET), Hällsten and
colleagues studied the effects of 26-weeks of rosiglitazone (4 mg
twice daily) or metformin (1000 mg twice daily) treatment
in 45 newly diagnosed patients with T2DM (Hällsten et al.,
2002). Despite equal improvements in HbA1c, insulin stimulated
muscle glucose uptake and exercise-induced glucose uptake (65-
min of single-leg knee-extension at 10% of maximal isometric
force) was augmented in the rosiglitazone group but not in the
metformin-treated patients (Hällsten et al., 2002). These findings
are, however, in keeping with the mechanisms of actions of
these drugs. Besides insulin sensitizers, insulin secretagogues
have also been studied. Larsen et al. (1999) found that the
blood glucose lowering actions of the sulfonylurea glibenclamide
(7 mg) and exercise (60-min at 57% of VO2max) are additive
in patients with T2DM. Similarly, Massi-Benedetti et al. (1996)
studied the glucose and insulin responses to a single exercise
bout in 167 patients with T2DM treated for 14–28 days with
glimepiride (3 mg/day) or glibenclamide (10 mg/day). They
found that 1-h of cycling at 120 bpm reduced blood glucose
in both groups, but lowered endogenous insulin secretion (as
shown by reduced C-peptide levels) in the glimepiride group
only (Massi-Benedetti et al., 1996). This likely indicates that
glimepiride, but not glibenclamide, treatment also increases
insulin- and/or- exercise-induced glucose uptake. This idea is
supported by in vitro observations from Haupt and colleagues
who showed that glimepiride activates PI3 kinase and increases
insulin-stimulated glycogen synthesis in human primary skeletal
muscle cells, where glibenclamide has no effect (Haupt et al.,
2002).
While the majority of T2DM patients will use metformin
and other anti-hyperglycemic drugs, insulin is used as a final
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approach and has been seldom studied in such patients in
the context of exercise. van Dijk et al. (2012) found that
24-h CGM-derived hyperglycemia (time above 7.8 mM) and
glycemic variability was reduced in sixty patients who had
completed a 45–60-min cycling bout at 30–50%Wmax, and
that this improvement was not different between insulin-treated
or insulin-naïve patients (Van dijk et al., 2013). The same
study also reported inter-individual differences in changes in
mean 24-h glucose, finding poorer glycemic variability in nine
(15%) of the sixty patients (Van dijk et al., 2013). Furthermore,
while the study found that the prevalence of hypoglycemia
was greater in insulin-treated patients compared with non-
insulin-treated patients, this was not influenced by exercise.
While hypoglycemia is a common fear and consequence of
the use of exercise in insulin-treated diabetes patients, the risk
of hypoglycemia can be dramatically reduced through proper
instruction, advice, and guidance on carbohydrate intake and
insulin-meal-exercise timing [some guidance is given ADA
guidelines (American Diabetes Association, 2018b)]. This is a
very important consideration that is beyond the intended aim
of this review but studies addressing the effect of exercise on
the prevalence and inter-individual variability of hypoglycemia
in T2DM are lacking.
Besides anti-hyperglycemia drugs, lipid-lowering HMG-CoA
reductase inhibitors (e.g., statins) are commonplace in the
management of (pre)diabetes. In the 1990/2000s, it was shown
that statin use may lead to mitochondrial dysfunction and muscle
damage (Thompson et al., 1997; Päivä et al., 2005; Draeger
et al., 2006; Schick et al., 2007), prompting a hypothesis that
statin treatment may blunt the beneficial effect of exercise.
Meex et al. (2010) found that statin treatment (between 5
and 40 mg/day of atorvastatin, simvastatin, rosuvastatin, or
pravastatin) combined with regular aerobic plus resistance
training more robustly increased insulin sensitivity than training
alone. They observed equal weight loss and improved fitness
and muscle mitochondrial function between groups but no
improvements in fasting glucose or HbA1c (Meex et al., 2010).
While this work showed that statins unlikely impair exercise
adaptations to glucose metabolism and mitochondrial function,
with different dosing regimens and the inclusion of individuals
with/without diabetes treated with a mix of hyperglycemia-
lowering drugs (metformin and/or sulfonylureas), is it difficult
to ascertain the precise exercise-statin interaction from this
work. In 2013, two studies examined exercise-statin interactions.
Larsen and colleagues compared ten simvastatin-treated (10–
40 mg/day for ∼5-years) hypercholesterolemic patients with
untreated controls matched by age, weight, body mass index, fat
percentage and VO2max. They found lower insulin sensitivity,
lower muscle mitochondrial function, and higher HbA1c levels
in statin-treated patients (Larsen et al., 2013). Meanwhile,
Mikus et al. (2013) randomized thirty-seven obese individuals
with metabolic syndrome to 12-weeks of aerobic exercise with
or without simvastatin treatment (40 mg/day). They found
that exercise-induced improvements in VO2max and muscle
mitochondrial content were absent in the statin-treated group.
Again, these studies indicate potential for statins to influence
exercise-related factors but they do not allow one to conclude
whether statin use directly influences changes in blood glucose
control following exercise.
Other retrospective studies have also examined exercise-drug
interactions. For example, in 2014, a small study (N = 14)
by my group found that the increase in GLP-1- or arginine-
stimulated insulin secretion following a single exercise bout
was absent in T2DM patients who were drug-treated (Knudsen
et al., 2015). This is similar to the above-described findings
from Erickson et al. (2017b) who found blunted acute exercise-
induced improvements in postprandial glucose in patients treated
with multiple anti-hyperglycemics. However, Knudsen et al.
(2015) did not examine specific drugs and was not designed
to prospectively examine exercise-drug interactions. In their
retrospective analysis of outcomes from a 12-week training study
in patients with T2DM, Terada et al. (2013a) demonstrated that
greater reductions in blood glucose were found when diabetic
medications were taken less than 6-h prior to exercise compared
to more than 6-h. These observations suggest that drug-exercise
timing is important; however, outcomes were not derived from
controlled drug administration but from retrospective analyses
of patients’ drug diaries.
Unfortunately, published work that documents exercise-drug
interactions vary in their study designs and target populations,
and have mixed outcomes. Consequently, such work has not
informed current clinical guidelines. With the exception of a
brief comment on insulin-activity timing (American Diabetes
Association, 2018c), as of 2018 no information regarding
exercise-drug timing is currently provided in the ADA guidelines
for preventing and treating T2DM. Although there is an urgent
need for a larg-scale prospective trial specifically examining
the interactions between anti-hyperglycemic medications and
exercise to optimize blood glucose control for patients with
T2DM, based on the equivocal evidence available it seems likely
that bespoke and carefully monitored exercise-drug timing and
dosing is required for patients on an individual basis.
F. Weight Loss
The independent effects of exercise and weight loss on blood
glucose control in (pre)diabetes have been well studied, showing
that either approach may improve blood glucose control or
insulin sensitivity (Goodpaster et al., 2003; Solomon et al.,
2008, 2009; Dubé et al., 2011). However, their interactive
effects are less understood. Furthermore, a lack of energy
balance and prevention of consequent weight loss confounds the
interpretation of many exercise studies. For example, we found
that interval walking training improved blood glucose control in
T2DM patients whereas continuous walking did not; however,
interval walkers also displayed greater reduction in body fat mass,
precluding a firm conclusion that the benefit was induced by
interval walking per se (Karstoft et al., 2013).
Although data from Goodpaster et al. (2003) demonstrated
the additive effects of diet-induced weight loss (10% of body
mass via a 500–1000 kcal/day deficit) and exercise training
(40 min at 75% HRmax, 4–6 times/week) on insulin sensitivity,
their work did not reveal additive effects on blood glucose
control (fasting glucose, or 2-h OGTT glucose). Our work
also previously found that improvements in fasting glucose,
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2-h OGTT glucose, or insulin sensitivity were equal in obese
individuals with prediabetes randomized to 12-weeks of exercise
training (60 min/day at 65% VO2max, 5 days/wk) either with
or without 500 kcal/day deficit-induced weight loss (Solomon
et al., 2008, 2009). A following study from Goodpaster et al.
(2010) found that delaying initiation of physical activity during
a weight loss intervention in severely obese individuals had no
influence on metabolic outcomes, including improved fasting
glucose at 6-months. That said, other studies have found that
exercise is critical for maintaining improved glucose control. For
example, Thomas and colleagues carefully examined the effects of
weight regain on cardiometabolic risk factors following 6-months
weight loss (10% of body weight via deficit of 600 kcal/day) with
supervised exercise (walking at 60% of VO2max, 400 kcal/session,
5 days/week) in 100 metabolic syndrome patients (Thomas et al.,
2010). They found that individuals randomized to continue
exercise during controlled weight regain following initial weight
loss, maintained improved blood glucose control while most
metabolic variables deteriorated in those who ceased exercise
(Thomas et al., 2010). Bouchonville et al. (2014) reported
that fasting glucose, and glucose AUC and insulin sensitivity
measured during OGTT were more robustly improved following
12-months of diet-induced weight loss (10% of body weight)
plus exercise (90-min of combined aerobic and resistance, thrice
weekly) when compared to either weight loss or exercise alone,
in 100 obese individuals. The additional benefit conveyed by
exercise plus diet-induced weight loss is supported by other
recent work (Weiss et al., 2015; Francois et al., 2018). But the
importance of exercise alone is also underpinned by outcomes
from the IDES trial: Balducci et al. (2012) found that the
magnitude of increase in fitness following exercise training (twice
weekly supervised aerobic and resistance training plus exercise
counseling) predicts improvement of cardiometabolic risk factors
including HbA1c, independent of weight loss.
We currently lack precise information regarding the
interaction between exercise and weight loss from large-
scale randomized controlled trials in order to update clinical
guidelines. Nonetheless, the above-described observations
underpin the necessity of regular exercise to maintain and/or
maximize the benefits of weight loss on blood glucose control in
individuals with (pre)diabetes. Current clinical guidelines do not
convey this sentiment.
G. Inactivity/Sitting Time
From the early 2000s, data has emerged that physical inactivity
(daily time spent being sedentary, i.e., sitting or lying while
awake) is strongly associated with T2DM risk and interacts with
the level of physical activity (Dunstan et al., 2004; Wilmot et al.,
2012). This provides evidence that the amount of daily inactivity
may influence the inter-individual variability in changes in blood
glucose control following exercise training. Further evidence has
also emerged demonstrating that interrupting sitting time can be
a useful intervention for preventing and managing blood glucose
control (reviewed in Dempsey et al., 2016). Additionally, in the 45
and up study published in van der Ploeg et al. (2012), association
analyses showed that patients with T2DM must increase their
physical activity level and reduce their sedentary time in order
to reduce mortality. Such evidence has prompted the ADA to
include a statement in their standards of medical care stating that,
in addition to increased physical activity and regular exercise,
individuals should reduce their sedentary time by breaking up
prolonged bouts of sitting with light activity for a few minutes
at least every 30 min (Table 2) (American Diabetes Association,
2018b). However, since large scale randomized controlled trials
examining such phenomena in patients with T2DM are lacking,
this guideline is not wholly evidence-based. Furthermore, it
is not known when an interruption to sitting time would be
best initiated, i.e., in the postabsorptive or postprandial state
(see Exercise-Meal Timing). Additionally, training studies in
diabetes patients seldom report objectively measured physical
activity/inactivity levels; consequently, the influence of inactivity
on the variability in glycemic outcomes following training is
unknown. With advances in tri-axial accelerometry, methods for
objectively quantifying sitting time and the transition to standing
and activity can be easily implemented with increasing accuracy
and low cost. As new data emerges over the coming years, clinical
guidelines related to the interruption of sedentary time will be
further optimized. In relation to this, since an exercise bout
may influence total daily activity levels (Thompson et al., 2014),
prospective trials are required to understand the impact of this on
glucose control in diabetes.
H. (Epi)genetics
Genome wide association studies have identified several genes
associated with increased risk of developing T2DM (reviewed
in Prasad and Groop, 2015). Some of these genes are also
associated with glycemic outcomes from weight loss lifestyle
interventions, such as the Diabetes Prevention Program and
the Diabetes Prevention Study (reviewed in Weyrich et al.,
2007). With specific reference to the effect of exercise training
on blood glucose control, far fewer genetic studies have been
published. As described earlier in this paper, the HERITAGE
family study demonstrated large heterogeneity in glycemic
outcomes following a 20-week exercise training intervention,
where approximately 40% of the participants showed no change
or an adverse direction of change in IVGTT-derived parameters
of blood glucose control (Boulé et al., 2005). Findings from
the HERITAGE family study have shown that leptin and leptin
receptor gene polymorphisms and a leptin gene trait locus on
7q31 are associated with training-induced changes in the insulin
response to IVGTT and fasting insulin, respectively (Lakka et al.,
2003, 2004). Rate of glucose disappearance, insulin sensitivity,
and disposition index during IVGTT are also improved more
following training in C allele carriers at rs2180062 in the
FHL1 gene than in the T allele carriers (Teran-Garcia et al.,
2007). Although the HERITAGE family study did not examine
individuals with prediabetes or T2DM, in 2010 the study
investigators examined whether 8 T2DM susceptibility variants
(single nucleotide polymorphisms, SNPs, previously identified
through genome-wide linkage analyses) could modulate changes
in IVGTT-derived measures of glycemic control following
20 weeks of regular exercise training (Ruchat et al., 2010). After
adjustment for multiple comparisons and adjusting for weight
loss (change in waist circumference), the authors identified that
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a Pro12Ala SNP in the PPARγ gene accounted for statistically
significant variance in exercise-induced changes in the glucose
disappearance rate (1Kg , 2.81% of variance explained) glucose
effectiveness (1Sg , 1.83%), the acute insulin secretory response
to glucose (1AIRg , 0.94%), and the disposition index (1DI,
2.15%) (Ruchat et al., 2010). The authors also found that carriers
of the Ala allele had greater exercise-induced improvements
in these IVGTT-derived variables (Ruchat et al., 2010). The
findings from this work advanced our knowledge; however, only
8 SNPs were selected and HbA1c or 2-h OGTT glucose were not
measured. Furthermore, since the publication date of that study
in 2010, several more SNPs associated with diabetes risk have
been identified. As such, there is a great need for similar studies in
individuals with prediabetes or T2DM. That said, in Klimentidis
et al. (2014) examined the influence of 65 T2DM-associated SNPs
on the relationship between physical activity level and genetic
risk score for T2DM. They found that the protective effect of
physical activity was weakest among individuals with high genetic
risk for T2DM. Their findings suggest that the role of physical
activity in the prevention of diabetes may be blunted in those with
high susceptibility for the disease. However, the causality of such
correlative findings must be confirmed.
Besides genetics, epigenetics have received little attention
in the context of the exercise and blood glucose control in
pre(diabetes). Barrès et al. (2012) measured whole genome
methylation as well as the methylation status of exercise
responsive genes (PGC-1α, PDK4, and PPAR-δ) in skeletal
muscle biopsies from healthy adults at rest and following a single
exercise bout. Exercise induced a dose-dependent expression
of PGC-1α, PDK4, and PPAR-δ, together with a marked
hypomethylation on their respective promoters. The authors
further showed that acute exercise caused a transient changes
in the pattern of DNA methylation in adult skeletal muscle
tissue (differentiated non-dividing somatic cells), and that DNA
methylation was unaltered following 3-weeks of training despite
increased RNA expression of PGC-1α and TFAM promoters
(Barrès et al., 2012). This was a seminal observation in exercise
biology since it demonstrated that DNA hypomethylation is a
likely a transient mechanism involved in mRNA synthesis and
that epigenetic regulation of the genome is dynamic to acute
stimuli. However, whether promoter hypomethylation induces a
functional influence on blood glucose control from exercise in
individuals with (pre)diabetes, remains to be investigated.
In data published in 2015 from the HART-D study, a large-
scale randomized controlled trial which determined the effect of
9-months of supervised exercise training on HbA1c in patients
with T2DM, Stephens et al. (2015) measured the baseline
skeletal muscle transcriptome before the intervention. The
authors identified 186 genes with differential mRNA expressions
between “responders” (training-induced decrease in HbA1c) and
“non-responders” (no change in HbA1c) of which ∼25% of
these differentially expressed genes were involved in substrate
metabolism and mitochondrial dynamics (Stephens et al., 2015).
Targeted qRT-PCR analyses of a selection of genes from their
array demonstrated that the lack of training effect on HbA1c was
linked to lower baseline expression levels of exercise-responsive
genes. These included PPARα and ELOVL1, which play a role
in lipid metabolism, and CHKB, CISD2, and FOXO1, which
are involved in mitochondrial function. Such findings prove
very useful in identifying molecular biomarkers of exercise
effectiveness in T2DM, and individualized follow-up studies of
the “non-responders” are needed in order to understand how
their therapeutic benefit from exercise can be achieved.
From the data we have available in 2018, identified
genetic/epigenetic/transcriptomic factors explain only a small
amount of the variability in outcomes following training. For
example, the HERITAGE family study found that less than 5%
of the variance in glycemic outcomes following training was
explained by 8 T2DM susceptibility variants (Ruchat et al., 2010).
As -omics technologies improve and become more widespread
and more accessible in exercise science, there is no doubt that
metabolite, protein, and microRNA signatures, as well as DNA
methylation loci, which predict the magnitude of the therapeutic
effect of exercise on blood glucose control in individuals with
(pre)diabetes will be identified. Evidence to support this notion
was presented by Rowlands et al. (2014) who found multiple
alterations in the transcriptome, the methylome, and microRNA
arrays following 16-weeks of resistance or endurance training
in obese Polynesian individuals with T2DM. Due to a lack
of evidence, as of 2018 the ADA guidelines do not include
any information on molecular biomarkers which may be used
to inform exercise prescription. This is very likely to change
over the next 10-years, particularly as outcomes from studies
like the Molecular Transducers of Physical Activity Consortium
(MoTrPAC) evolve.
I. Direct Effect of Hyperglycemia and
Poor Beta-Cell Function
Chronic exposure to high glucose levels deteriorates cellular
function and/or causes apoptosis in tissues that regulate blood
glucose control. For example, several groups including my own
have found that in vitro exposure of differentiated skeletal muscle
cells (myotubes) to prolonged (>24-h) hyperglycemia reduces
insulin-stimulated glucose uptake (Aas et al., 2011; Green et al.,
2012). Solomon et al. (2012) we confirmed these observations in
humans showing that elevation of plasma glucose 5 mM above
basal for 24-h reduced insulin sensitivity in healthy volunteers.
Furthermore, primary myotubes isolated from hyperglycemic
donors exhibit blunted muscle cell adaptations to electrical pulse
stimulated contractions (Feng et al., 2015). Therefore, in vitro
observations prompt one to hypothesize that chronic exposure
to high blood glucose levels (the phenotype of T2DM) may
blunt beneficial exercise adaptations. To test this hypothesis,
in 2013 we examined the relationship between pre-intervention
blood glucose control (HbA1c, fasting glucose, and 2-h OGTT
glucose) and changes in glucose control following 3–4-months
of exercise training (∼4–5 days/week, up to 60 min/session at
60–70% HRmax) in 105 individuals with prediabetes or T2DM.
Interestingly, we found a U-shaped relationship suggesting that
individuals with relativity well controlled hyperglycemia respond
well to training while patients with poor blood glucose control
have poor improvements or even a deterioration in blood glucose
control following training (Solomon et al., 2013a). Another
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study found that fasting hyperglycemia was also associated
with blunted improvements in 2-h OGTT glucose following 3-
months of aerobic training in older obese individuals (Malin
and Kirwan, 2012). Furthermore, the STRRIDE study found an
inverse correlation between baseline fasting glucose and aerobic
training-induced improvement in insulin sensitivity (Si from
IVGTT) in overweight individuals: Si increased in participants
with normal fasting glucose (<5.6 mM) but decreased in those
with impaired fasting glucose (≥5.6 mM) (AbouAssi et al., 2015).
However, these are correlational observations that do not imply
causality and may be confounded by other influential variables.
Additionally, some studies dispute a role for hyperglycemia in
blunting the therapeutic action of exercise. Terada et al. (2013a)
found that higher pre-exercise blood glucose concentrations were
associated with greater decreases in blood glucose following a
single exercise bout in patients with T2DM. Accordingly, van
Dijk and colleagues demonstrated that greater HbA1c levels
in T2DM patients correlated with greater decreases in mean
glucose over the 24-h period following a single exercise bout
(Van dijk et al., 2013). However, since the findings from Terada
and van Dijk derive from single exercise bouts, they should not
be extrapolated to reflect expected outcomes following chronic
training.
To help understand the physiological mechanisms that
potentially link hyperglycemia with exercise adaptations, the
HERITAGE Family study demonstrated that pre-intervention
glucose tolerance (Kg during IVGTT) influences training induced
changes in glucose-stimulated insulin secretion (AIRg during
IVGTT) (Boulé et al., 2005). Boulé et al. (2005) found that
in healthy non-diabetic subjects, training decreased AIRg in
individuals in the quartile with the highest Kg at baseline while
AIRg increased in those in the quartile with the lowest Kg. We
repeated this work in people with prediabetes and T2DM, finding
that exercise-induced improvements in blood glucose control
were lowest in those with poorer pre-intervention pancreatic
beta-cell function (Solomon et al., 2013b). This observation
supports earlier work in patients with T2DM from Krotkiewski
et al. (1985), and is complemented by a study conducted by
Dela et al. (2004) who found that T2DM patients with a low
C-peptide response to glucagon infusion had no improvement
in glucose- or arginine-stimulated insulin secretion following 3-
months of aerobic training. In vitro incubation of pancreatic
beta-cell lines or primary islets in high glucose-containing
medium reduces glucose-stimulated insulin secretory function
(Donath et al., 1999; Maedler et al., 2002), findings we have
also translated into human observations (Solomon et al., 2012).
So it may be speculated that chronic exposure to high glucose
levels may directly blunt otherwise beneficial exercise-mediated
adaptations in the endocrine pancreas. In a pilot project to
test that hypothesis, in 2013 we stratified T2DM patients with
respect to their HbA1c value and examined insulin secretory
function following a single exercise bout (Knudsen et al., 2015).
We found that GLP-1 and arginine-mediated potentiation of
glucose-stimulated insulin secretion was augmented by exercise
in patients with well controlled glycemia (HbA1c < 6%) but
worsened in patients with poor glucose control (HbA1c > 6%)
(Knudsen et al., 2015). Although this was a small pilot
study, it is the first evidence that causally links chronic
exposure to hyperglycemia with blunted exercise adaptations in
diabetes patients. In combination with above-described work
(Krotkiewski et al., 1985; Dela et al., 2004; Solomon et al.,
2013b), such data suggest that T2DM patients with poor beta-
cell insulin secretory function may not optimally respond to
exercise treatment modalities. Research studies are required to
determine whether optimizing insulin secretory function in such
patients prior to initiating training may restore beneficial exercise
adaptations. Chronic cellular exposure to high glucose levels is
typically linked with apoptosis driven by inflammation and/or
oxidative stress, a process called glucotoxicity (Poitout and
Robertson, 2008). However, it remains to be determined whether
inflammatory or oxidative stress mechanisms underpin high
glucose-induced prevention of beneficial exercise adaptations.
No study to date has examined whether exposure
to experimental hyperglycemia (via infusion) or rapid
normalization of hyperglycemia in diabetes patients (via insulin
or sodium-glucose cotransport inhibitors drugs) can influence
exercise adaptations. It remains to be investigated whether
glucotoxicity directly influences exercise training-induced
improvements in blood glucose control. Knowledge gained
from answering such a research question would further inform
ADA guidelines and therefore enable clinicians to enhance the
management of their patients’ hyperglycemia. Such knowledge
would also help individualize lifestyle intervention approaches if
indeed glucose lowering and/or beta-cell optimizing therapy is
required in some patients prior to initiating an exercise regime.
Since several other descriptive characteristics such as age, sex,
race, body weight, or duration of diabetes (years since diagnosis)
or specific dietary nutrients, may independently influence the
above described contributing factors, one may speculate that
these may influence exercise-mediated effects on blood glucose
control in patients with (pre)diabetes. The same may also be true
of activity compensation where an exercise bout may negatively
influence total daily activity levels (Thompson et al., 2014).
Family history of diabetes should also be considered in future
work since individuals with a diabetic parent exhibit a blunted
post-exercise insulin-mediated glycogen storage response (Price
et al., 1996). However, following regression analyses in one of my
own studies (Solomon et al., 2013b), neither age, BMI, sex, or time
since diabetes diagnosis had any influence on the hyperglycemia-
lowering effect of exercise training. Regression analyses from
van Dijk and colleagues also support that neither age, BMI,
diabetes duration, or drug treated influence exercise-induced
blood glucose control in patients with T2DM (Van dijk et al.,
2013). That said, no study has prospectively examined the role
of such variables on blood glucose control following training in
individuals with prediabetes or T2DM. One exception may be the
Look-AHEAD study, a randomized controlled trial examining
the effect of an intensive lifestyle intervention (combined diet
and exercise induced weight loss) on T2DM remission in 5145
patients. The investigators found that longer-term remission
(after 2 to 4-years follow-up) was more likely in patients not using
insulin with less than 2-year duration of diabetes, a lower baseline
HbA1c, and a greater first-year weight loss (Gregg et al., 2012).
Although Look-AHEAD was not an exercise training study per se,
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FIGURE 3 | Evidence-based sources of inter-individual variability in the blood glucose lowering effects of exercise in individuals with prediabetes or T2DM. Other
sources that have not been adequately studied to conclusively state that they contribute to this variability in individuals with prediabetes or T2DM include age, sex,
race, body weight, family history of diabetes, and duration of diabetes.
TABLE 3 | Science gaps which, if filled, will increase our understanding of inter-individual variability in the therapeutic blood glucose lowering effect of exercise for
individuals with prediabetes and/or type 2 diabetes.
Science gaps
1 A randomized controlled trial of exercise training to determine the patient-by-treatment interaction for the change in blood glucose control (HbA1c, fasting
glucose, and 2-h OGTT glucose) is needed in people with prediabetes and T2DM. This would help accurately quantify inter-individual variability and identify true
non-responders.
2 A study to determine the inter-individual variability in blood glucose control caused by different exercise doses (frequency, intensity, and time) is needed in
individuals with prediabetes or T2DM.
3 A study to determine the inter-individual variability in blood glucose control caused by different types of exercise is needed in individuals with prediabetes or
T2DM.
4 A description of psychological barriers, behavioral barriers, and environmental barriers to implementing lifestyle changes and incorporating exercise into
diabetes treatment should be included in clinical guidelines.
5 A study to determine the optimal exercise-meal timing needed to maximize postprandial glucose control in individuals with prediabetes or T2DM is required.
6 There is an urgent need for a large-scale prospective trial specifically examining the interactions between exercise and anti-hyperglycemic medications to
optimize blood glucose control for patients with T2DM.
7 A large scale randomized controlled trial examining the interruption of sitting time with light activity (and its pre-postprandial timing) in patients with T2DM is
needed.
8 There is a need for studies to identify metabolite, protein, or microRNA signatures, as well as DNA methylation loci, which predict the magnitude of the
therapeutic effect of exercise on blood glucose control in individuals with prediabetes of T2DM.
9 A study determining whether exposure to experimental hyperglycemia (via infusion) or rapid normalization of hyperglycemia in diabetes patients (via insulin or
sodium-glucose cotransport inhibitors drugs) can directly influence exercise adaptations is needed.
10 Exercise dose (including frequency, intensity, and time above habitual activity levels), exercise type, exercise adherence, exercise-meal timing, exercise-drug
timing, and drug name and dosing, and objectively measured physical activity levels and sedentary time, should always be considered in a study design and be
reported in publications.
These future approaches will optimize clinical exercise guidelines, and ultimately help maximize the therapeutic blood glucose lowering effects for all patients. Further detail
and references are in the main text.
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it does indeed highlight factors to be considered in future exercise
studies.
In the free-living “real world” setting, all of the above-
described contributing factors play a role in the notable
heterogeneity in the therapeutic blood glucose lowering response
to exercise in people with (pre)diabetes. In the lab setting, where
exercise is supervised and standardized, the influence of several of
these above-described sources of variability, particularly exercise
adherence, can be controlled and therefore minimized. Yet, in the
free-living “real world” setting there are behavioral (desire, self-
image, motivation) and environmental (climate, weather, terrain)
barriers combined with abundant access to activity reducing
transport modalities (cars, busses, trains, elevators, escalators,
conveyer belts) which influence the adherence to exercise and
thereby encourage an inactive lifestyle. Thus, the true challenge
to maximizing the therapeutic potential of exercise is immense.
WHERE DO WE GO FROM HERE?
The purpose of this review was to examine inter-individual
variability in the blood glucose lowering effect of exercise
in individuals with T2DM, and to identify the sources of
such variability. Interpretations should not be extrapolated
to other variables (e.g., lipids, blood pressure, etc.), nor
should a non-response in blood glucose control following
exercise be considered to convey a non-response in other
variables. Due to a lack of standardization of study design,
differences in methods/assays, variations in timing of post-
training measurements, heterogeneity of subject demographics
between trials, and probably most importantly, a lack of
measurement of clinical diagnostic measures for assessing blood
glucose control, a systematic review and meta-analysis on this
topic is not possible. However, from the evidence presented above
it is highly likely that inter-individual variability in the changes
in blood glucose control following exercise exists in the context
of T2DM and that true non-responders will be identified. In
doing so, one must be aware that “non-responder” does not mean
“never responder.” Identifying an adverse outcome to a particular
intervention should be embraced as a challenge to overcome.
By doing so, the knowledge gained will ultimately maximize the
therapeutic benefits of exercise for all patients.
Going forward, several sources of variability have been
identified (Figure 3), and I propose that exercise dose (including
frequency, intensity, and time above habitual activity level),
exercise type, exercise adherence, exercise-meal timing, exercise-
drug timing, and drug name and dosing, and objectively
measured physical activity level and sedentary time, should
always be considered in a study design and reported in
publications. Among many published studies, I admit that I too
have been guilty of not always including such details in my
papers, either through accidental omission or failure to record
such data. Remedying this in future will increase the quality of
work in the field and enable comparisons between independent
studies. This would facilitate the accurate calculation of technical
error of measurement and eventually establish an evidence-
based “reference range” indicative of a clinically meaningful
exercise-induced improvement in blood glucose control. Such
an approach would then enhance the reliability of information
used to inform clinical guidelines. That said, Table 3 highlights
the current science gaps that must be urgently filled if we
are to understand how to maximize the therapeutic benefit
of exercise on blood glucose control for all individuals with
prediabetes or T2DM. The new knowledge that will emerge
in the next 5–10 years will couple genetic, transcriptomic,
epigenetic, and physiological factors with knowledge of exercise
dosing, exercise-meal timing, and exercise-drug interactions
to help maximize the therapeutic benefit of exercise for all
individuals, including those at risk of developing diabetes or
those already with T2DM. This creates great confidence that we
will soon successfully control the incidence of this preventable
disease.
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